Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 6/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274889 | 1.00 | TYMP (0.43) | TYMPBRD4TMIGD3TYMSTRPM2 | |
| SCHEMBL29709093 | 0.92 | TYMP (0.45) | TYMPBRD4TMIGD3TYMSEGFR | |
| SCHEMBL29709101 | 0.92 | TYMP (0.45) | TYMPBRD4TMIGD3TYMSEGFR | |
| SCHEMBL23215660 | 0.92 | TYMP (0.45) | TYMPBRD4TMIGD3TYMSEGFR | |
| SCHEMBL23215200 | 0.92 | TYMP (0.45) | TYMPBRD4TMIGD3TYMSEGFR | |
| SCHEMBL3627000 | 0.86 | TYMP (0.46) | TYMPTYMS | |
| SCHEMBL3626996 | 0.86 | TYMP (0.46) | TYMPTYMS | |
| SCHEMBL26647641 | 0.85 | TYMP (0.45) | TYMPTYMS | |
| SCHEMBL26647525 | 0.85 | TYMP (0.45) | TYMPTYMS | |
| SCHEMBL30274796 | 0.85 | TYMP (0.44) | TYMPTYMSKDRADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD (SG) | 2025-08-21 | — | — | US | disclosed |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-05-01 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| EP-4507700-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2025-02-19 | — | — | EP | disclosed |
| EP-4404942-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023201095-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023049477-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | TYMP 82/4885BRD4 3893/4885TMIGD3 4502/4885 |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | ADAR, RNGTT, NSUN2 | TYMP 36/4885BRD4 4771/4885TMIGD3 4420/4885 |
| US-20250135036-A1 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | MECP2, ADAR, NSUN2 | TYMP 1801/4885BRD4 1124/4885TMIGD3 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.